Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292)
NCT 04862663 Brief Summary A Phase Ib/III Open-label, Randomised Study of Capivasertib…
Read more arrow_forwardNCT 04862663 Brief Summary A Phase Ib/III Open-label, Randomised Study of Capivasertib…
Read more arrow_forwardNCT 05666700 Brief Summary This clinical trial will investigate the in vivo…
Read more arrow_forwardNCT 05352672 Brief Summary This study is researching an experimental drug called…
Read more arrow_forwardNCT 05523947 Brief Summary This first-in-human study will be counducted to evaluate…
Read more arrow_forwardACTRN 12623000640606 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardACTRN 12623001338651 Brief Summary The purpose of this trial is to assess…
Read more arrow_forwardNCT 05868174 Brief Summary This is an open label, single-arm, multicentre dose…
Read more arrow_forwardNCT 05756907 Brief Summary This is a Phase 1b/2a, open-label, adaptive-design outpatient…
Read more arrow_forwardNCT 05694936 Brief Summary The aim of this study is to determine…
Read more arrow_forwardNCT 06907641 Brief Summary The goal of this clinical trial is to…
Read more arrow_forwardACTRN 12618001480279 Brief Summary The purpose of this study is to assess…
Read more arrow_forward